New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC
- PMID: 35831561
- PMCID: PMC9345916
- DOI: 10.1038/s41416-022-01905-4
New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC
Abstract
Colorectal peritoneal metastases (CRPM) can be resistant to the chemotherapy agent (oxaliplatin) most employed, up until recently, as hyperthermic intraperitoneal chemotherapy (HIPEC). Glutathione-mediated inactivation of oxaliplatin can be substantially reduced by genomic deletion of the gene or pharmacological inhibition of glutamate-cysteine ligase in CRPM tumouroids. These discoveries may rekindle the enthusiasm for HIPEC in concert with cytoreductive surgery, which has been employed to manage patients with this once-nihilistic form of stage-IV disease.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
RGR receives research and engineering support from Fisher and Paykel Healthcare, as well as travel and accommodation expenses and research support from the National Health and Medical Research Council of Australia. RGR is the President of the International Society for the Study of the Pleura and Peritoneum (ISSPP), Group Leader of the Differentiation and Transcription Laboratory and a Professor with The Sir Peter MacCallum Department of Oncology and Department of Clinical Pathology, The University of Melbourne. MF is a general surgeon and PhD candidate at The University of Melbourne, Australia.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical